Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Bio (NASDAQ:TVGN) had its price target lowered by analysts at D. Boral Capital from $10.00 to $5.00. They now have a "buy" rating on the stock.
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q [Yahoo! Finance]